INCYTE CORP (INCY) Stock Fundamental Analysis
NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
Taking everything into account, INCY scores 6 out of 10 in our fundamental rating. INCY was compared to 559 industry peers in the Biotechnology industry. INCY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INCY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make INCY a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year INCY was profitable.
INCY had a positive operating cash flow in the past year.
Of the past 5 years INCY 4 years were profitable.
Of the past 5 years INCY 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 0.37%, INCY belongs to the best of the industry, outperforming 89.98% of the companies in the same industry.
INCY has a Return On Equity of 0.58%. This is amongst the best in the industry. INCY outperforms 91.23% of its industry peers.
The Return On Invested Capital of INCY (4.67%) is better than 93.02% of its industry peers.
INCY had an Average Return On Invested Capital over the past 3 years of 7.24%. This is significantly below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.37% | ||
| ROE | 0.58% | ||
| ROIC | 4.67% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
INCY has a Profit Margin of 0.48%. This is amongst the best in the industry. INCY outperforms 90.70% of its industry peers.
INCY's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 5.39%, INCY belongs to the best of the industry, outperforming 92.84% of the companies in the same industry.
INCY's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 93.19%, INCY belongs to the best of the industry, outperforming 93.92% of the companies in the same industry.
INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.39% | ||
| PM (TTM) | 0.48% | ||
| GM | 93.19% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so INCY is destroying value.
The number of shares outstanding for INCY has been reduced compared to 1 year ago.
INCY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for INCY is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.92 indicates that INCY is not in any danger for bankruptcy at the moment.
INCY has a better Altman-Z score (4.92) than 78.00% of its industry peers.
The Debt to FCF ratio of INCY is 0.12, which is an excellent value as it means it would take INCY, only 0.12 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.12, INCY belongs to the best of the industry, outperforming 96.42% of the companies in the same industry.
INCY has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.01, INCY perfoms like the industry average, outperforming 42.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 4.92 |
ROIC/WACC0.49
WACC9.55%
2.3 Liquidity
INCY has a Current Ratio of 2.04. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
INCY's Current ratio of 2.04 is on the low side compared to the rest of the industry. INCY is outperformed by 75.13% of its industry peers.
INCY has a Quick Ratio of 2.00. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
INCY's Quick ratio of 2.00 is on the low side compared to the rest of the industry. INCY is outperformed by 74.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.04 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
INCY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.45%.
INCY shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.21% yearly.
Looking at the last year, INCY shows a quite strong growth in Revenue. The Revenue has grown by 17.13% in the last year.
The Revenue has been growing by 14.46% on average over the past years. This is quite good.
EPS 1Y (TTM)-51.45%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%81.25%
Revenue 1Y (TTM)17.13%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%19.53%
3.2 Future
INCY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.55% yearly.
Based on estimates for the next years, INCY will show a decrease in Revenue. The Revenue will decrease by -0.43% on average per year.
EPS Next Y348.67%
EPS Next 2Y130%
EPS Next 3Y88.04%
EPS Next 5Y27.55%
Revenue Next Year12.03%
Revenue Next 2Y11.25%
Revenue Next 3Y10.64%
Revenue Next 5Y-0.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 37.23 indicates a quite expensive valuation of INCY.
Based on the Price/Earnings ratio, INCY is valued cheaper than 93.56% of the companies in the same industry.
INCY is valuated rather expensively when we compare the Price/Earnings ratio to 26.60, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 9.81, the valuation of INCY can be described as reasonable.
Based on the Price/Forward Earnings ratio, INCY is valued cheaper than 96.42% of the companies in the same industry.
INCY is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.39, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.23 | ||
| Fwd PE | 9.81 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaply inside the industry as 93.56% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, INCY is valued cheaply inside the industry as 93.20% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.81 | ||
| EV/EBITDA | 30.81 |
4.3 Compensation for Growth
INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INCY may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 88.04% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y130%
EPS Next 3Y88.04%
5. Dividend
5.1 Amount
INCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:INCY (6/13/2025, 12:26:00 PM)
68.505
-0.72 (-1.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.01%
Inst Owner Change2.91%
Ins Owners1.98%
Ins Owner Change6.35%
Market Cap13.26B
Analysts74.55
Price Target75.65 (10.43%)
Short Float %5.01%
Short Ratio4.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.95%
Min EPS beat(2)-10.01%
Max EPS beat(2)11.9%
EPS beat(4)1
Avg EPS beat(4)-3.77%
Min EPS beat(4)-14.75%
Max EPS beat(4)11.9%
EPS beat(8)3
Avg EPS beat(8)-3.5%
EPS beat(12)5
Avg EPS beat(12)-5.19%
EPS beat(16)7
Avg EPS beat(16)-6.87%
Revenue beat(2)2
Avg Revenue beat(2)2.51%
Min Revenue beat(2)1.09%
Max Revenue beat(2)3.94%
Revenue beat(4)3
Avg Revenue beat(4)2.09%
Min Revenue beat(4)-0.21%
Max Revenue beat(4)3.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.33%
Revenue beat(12)6
Avg Revenue beat(12)-0.19%
Revenue beat(16)9
Avg Revenue beat(16)0.35%
PT rev (1m)0.15%
PT rev (3m)-4.98%
EPS NQ rev (1m)0.49%
EPS NQ rev (3m)-2.46%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)-0.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.23 | ||
| Fwd PE | 9.81 | ||
| P/S | 3 | ||
| P/FCF | 43.81 | ||
| P/OCF | 34.66 | ||
| P/B | 3.62 | ||
| P/tB | 3.9 | ||
| EV/EBITDA | 30.81 |
EPS(TTM)1.84
EY2.69%
EPS(NY)6.98
Fwd EY10.19%
FCF(TTM)1.56
FCFY2.28%
OCF(TTM)1.98
OCFY2.89%
SpS22.8
BVpS18.95
TBVpS17.59
PEG (NY)0.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.37% | ||
| ROE | 0.58% | ||
| ROCE | 5.91% | ||
| ROIC | 4.67% | ||
| ROICexc | 16.3% | ||
| ROICexgc | 21.12% | ||
| OM | 5.39% | ||
| PM (TTM) | 0.48% | ||
| GM | 93.19% | ||
| FCFM | 6.86% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexcg growth 3Y-34.92%
ROICexcg growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score5
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.1 | ||
| Cap/Depr | 89.09% | ||
| Cap/Sales | 1.81% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 116.78% | ||
| Profit Quality | 1423.18% | ||
| Current Ratio | 2.04 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 4.92 |
F-Score5
WACC9.55%
ROIC/WACC0.49
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.45%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%81.25%
EPS Next Y348.67%
EPS Next 2Y130%
EPS Next 3Y88.04%
EPS Next 5Y27.55%
Revenue 1Y (TTM)17.13%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%19.53%
Revenue Next Year12.03%
Revenue Next 2Y11.25%
Revenue Next 3Y10.64%
Revenue Next 5Y-0.43%
EBIT growth 1Y-66.6%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year303.29%
EBIT Next 3Y78.87%
EBIT Next 5Y24.59%
FCF growth 1Y-47.44%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y-41.01%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%